Literature DB >> 11700835

Hereditary haemochromatosis: detection and management.

G Vautier1, M Murray, J K Olynyk.   

Abstract

Hereditary haemochromatosis is common, affecting one in 200 Australians of Anglo-Celtic descent; it results in iron overload affecting many organs, including the liver, heart, endocrine and musculoskeletal system. Diagnosis requires a high index of suspicion, as presenting symptoms and signs may be non-specific. Once suspected, hereditary haemochromatosis can be readily diagnosed by measurement of serum transferrin saturation and ferritin level, followed by genetic assessment. Homozygosity for the C282Y mutation in the HFE gene accounts for most cases in people of Anglo-Celtic descent in Australia; a genetic test for this mutation is widely available. Liver biopsy is advocated only in selected individuals at risk of cirrhosis or with an unclear diagnosis. Therapeutic phlebotomy remains the treatment and, if instituted early, will prevent many of the organ-specific complications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11700835     DOI: 10.5694/j.1326-5377.2001.tb143650.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  3 in total

1.  Changes in exercise capacity in subjects with cardiac asymptomatic hereditary hemochromatosis during a follow-up after 5 yrs.

Authors:  Yukitaka Shizukuda; Kevin P Smith; Dorothy J Tripodi; Ross Arena; Yu-Ying Yau; Charles D Bolan; Myron A Waclawiw; Susan F Leitman; Douglas R Rosing
Journal:  Am J Phys Med Rehabil       Date:  2012-05       Impact factor: 2.159

2.  Normal iron metabolism and the pathophysiology of iron overload disorders.

Authors:  Chiang W Siah; John Ombiga; Leon A Adams; Debbie Trinder; John K Olynyk
Journal:  Clin Biochem Rev       Date:  2006-02

Review 3.  Screening for hemochromatosis: patients with liver disease, families, and populations.

Authors:  Sumedha P Galhenage; Charlie H Viiala; John K Olynyk
Journal:  Curr Gastroenterol Rep       Date:  2004-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.